MedTrace Logo

Creatine Supplementation in Autism Spectrum Disorder

NCT04498078 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-12-22

No results posted yet for this study

Summary

Autism Spectrum Disorder (ASD) is accompanied by reduced levels of total creatine in right temporal-parietal junction and other brain regions of interest, and addressing this deficit by exogenous administration of creatine may have beneficial effects on brain metabolism and disease-specific clinical symptoms in patients suffering from ASD.

Conditions

Interventions

DIETARY_SUPPLEMENT

Creatine

Creatine monohydrate (20 g per day)

Sponsors & Collaborators

  • University of Novi Sad, Faculty of Sport and Physical Education

    lead OTHER

Principal Investigators

  • Sergej Ostojic, MD, PhD · Applied Bioenergetics Lab

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-15
Primary Completion
2025-05-01
Completion
2025-05-02

Countries

  • Serbia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04498078 on ClinicalTrials.gov